AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500
Debt
Debt-to-Equity Ratio-0.20
Current Ratio4.05
Quick Ratio4.00
Price-To-Earnings
Trailing P/E Ratio-3.64
Forward P/E Ratio-4.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.99 million
Price / Sales25.69
Cash FlowN/A
Price / CashN/A
Book Value($0.73) per share
Price / Book-5.48
Profitability
EPS (Most Recent Fiscal Year)($1.10)
Net Income$-51,500,000.00
Net Margins-909.33%
Return on EquityN/A
Return on Assets-62.92%
Miscellaneous
Employees41
Outstanding Shares51,320,000
AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
How were AcelRx Pharmaceuticals' earnings last quarter?
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) posted its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.01. The specialty pharmaceutical company earned $0.34 million during the quarter, compared to analyst estimates of $0.78 million. View AcelRx Pharmaceuticals' Earnings History.
What price target have analysts set for ACRX?
8 analysts have issued 12-month price targets for AcelRx Pharmaceuticals' stock. Their forecasts range from $2.00 to $8.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $5.50 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.
Who are some of AcelRx Pharmaceuticals' key competitors?
Some companies that are related to AcelRx Pharmaceuticals include CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), ANI Pharmaceuticals Inc Common Stock (ANIP), Theratechnologies (THERF), Vectura Group (VEGPF), Evolus (EOLS), Urogen Pharma (URGN), Amphastar Pharmaceuticals (AMPH), NuCana (NCNA), Abeona Therapeutics (ABEO), Homology Medicines (FIXX), Inflarx (IFRX), AMAG Pharmaceuticals (AMAG), Arcus Biosciences (RCUS) and CannTrust (CNTTF).
Who are AcelRx Pharmaceuticals' key executives?
AcelRx Pharmaceuticals' management team includes the folowing people:
- Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 55)
- Ms. Jane Wright-Mitchell, Chief Legal Officer (Age 49)
- Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
- Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
- Mr. Vincent J. Angotti, CEO & Director (Age 50)
Has AcelRx Pharmaceuticals been receiving favorable news coverage?
News articles about ACRX stock have trended somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 46.00 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are AcelRx Pharmaceuticals' major shareholders?
AcelRx Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include LEERINK REVELATION HEALTHCARE FUND I, L.P. (7.30%), INDUSTRY VENTURES SECONDARY VIII, L.P. (7.30%), Millennium Management LLC (0.45%), Northern Trust Corp (0.18%), A.R.T. Advisors LLC (0.14%) and GSA Capital Partners LLP (0.11%). Company insiders that own AcelRx Pharmaceuticals stock include Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.
Which major investors are selling AcelRx Pharmaceuticals stock?
Which major investors are buying AcelRx Pharmaceuticals stock?
ACRX stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and Northern Trust Corp. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.
How do I buy shares of AcelRx Pharmaceuticals?
Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AcelRx Pharmaceuticals' stock price today?
One share of ACRX stock can currently be purchased for approximately $4.00.
How big of a company is AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals has a market capitalization of $207.85 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.
How can I contact AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]
MarketBeat Community Rating for AcelRx Pharmaceuticals (ACRX)
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
